Assessment of safety and bleeding risk in the use of ECMO for multi-trauma patients: A multicentre review.
Respiratory failure is the most common form of organ failure following traumatic injury. Previously there have been concerns regarding ECMO use in the trauma setting due to the increased risk of bleeding and thrombotic complications. We sought to examine the management of trauma patients with ECMO and to assess the safety and outcome of its use. Data of all patients who experienced a traumatic injury and were supported with ECMO were collected from the five National Respiratory ECMO centres in the United Kingdom over the period from December 2011 to May 2017. Primary outcome variables included: 30 day and 6 month mortality and exacerbation of underlying traumatic injury post ECMO commencement. Secondary outcome variables included: duration of ECMO support, thrombotic complications and worsening of intracranial injury. 52 patients were identified. The overall hospital mortality was 15%. The incidence of bleeding complications was 50%, the majority of these not requiring intervention. Forty patients underwent surgical management prior to ECMO commencement, only 4 patients required take back to the operating theatre. There was no significant difference between the bleeding and non-bleeding group in time of injury to ECMO commencement (median difference 4.5 days; 95% CI -3 to 3 days, p = 0.75).There was no statistically significant difference between the bleeding and non-bleeding groups in regards to time to anticoagulation commencement after starting ECMO (median difference -1 hour; 95% CI -48 to 2 hours, p=0.29), or after trauma (median difference -1 day; 95% CI -4 to 2 days, p=0.41) (table 5). Nineteen patients were diagnosed with significant neurological injury. Twelve of these patients were anticoagulated. Two patients died as a direct result of worsening neurological injury. Our findings suggest that the use of ECMO in trauma patients does not exacerbate primary traumatic injury regardless of anticoagulation commencement and may confer a survival benefit. Neurological injury should not be seen as an absolute contraindication to ECMO. Level III, cohort study without external comparator.